Liposomal amphotericin B exposure in critically ill patients: a prospective pharmacokinetic study.
Med Mycol
; 60(10)2022 Oct 12.
Article
em En
| MEDLINE
| ID: mdl-36124725
L-AmB is marketed for decades to treat invasive fungal infections; however, not much is known about its exposure. We documented L-AmB exposure in 31 critically ill patients. Although median exposure was similar compared to noncritically ill patients, a considerable variability was observed.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Estado Terminal
/
Antifúngicos
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Animals
Idioma:
En
Revista:
Med Mycol
Ano de publicação:
2022
Tipo de documento:
Article